In a significant development, Chinese vaccine specialist CanSino Biologics Inc has been approved by Beijing to produce its COVID-19 vaccine candidate Ad5-nCOV, said a report from the state media citing documents from the China’s intellectual property regulator.

This is the first COVID-19 vaccine patent granted by China, said state-owned newspaper People’s Daily in a report.

The report cited documents published by China’s National Intellectual Property Administration stating that the patent was issued on August 11.

Incidentally, earlier this month, Saudi Arabia stated, it plans on commencing Phase III clinical trials of the CanSino vaccine.

CanSino is also reportedly in talks with Russia, Chile and Brazil to launch Phase III trials in those countries.

With the news reaching the market, CanSino’s Hong Kong shares surged by 14% in Monday’s morning session.

Categories: Creativity, Entrepreneurship, HR & Organization, Regulations & Legal, Strategy

Tags: Ad5-nCOV, approval, approved, Beijing, Brazil, CanSino Biologics Inc, CanSino vaccine, Chile, China, Chinese, clinical trials, coronavirus, COVID-19, COVID19, intellectual property regulator, National Intellectual Property Administration, patent, People’s Daily, Phase III, Russia, Saudi Arabia, vaccine, vaccine candidate, virus, Wuhan